The UK has a global opportunity to pioneer future medicines for age related disease clusters, writes the Medicines Discovery Catapult. 

Despite positively impacting employment, economic growth and delivering better medicines for patients, our Service and Supply companies are often-overlooked, says Chris Molloy.

Medicines Discovery Catapult's Helen Hind writes about the millions of blood and tissue samples stored in the UK that are not currently being used to best effect.

The Head of Virtual Drug Discovery at the Medicines Discovery Catapult writes about the UK’s industrial private sector drug discovery capabilities: "The UK is well positioned to take advantage of, and develop new markets for, the provision of virtual drug discovery services, connected through its experts and service providers".

The UK has been effective in translating AI research into new start-ups attracting both major investment and skilled workers from across the world. Combining this growth with a long-established expertise in drug discovery will maintain the UK’s position as leaders in these new and historical sectors, writes Medical Discovery Catapult. 

UK pharma R&D productivity is at an all-time low, warns Chris Molloy, but it’s not too late to create an ecosystem that will secure this sector’s future.